Close Menu

NEW YORK (360Dx) – Owlstone Medical announced today an investment by Aviva Ventures, the venture capital arm of insurance company Aviva, which that it will use to drive commercialization of its breath biopsy platform and test adoption.

The investment takes Owlstone Medical's total funding to $23.5 million since it was spun off from Owlstone Inc. in 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.